International Urogynecology Journal

, Volume 23, Issue 8, pp 983–991 | Cite as

Solifenacin for overactive bladder: a systematic review and meta-analysis

  • Deyi Luo
  • Liangren Liu
  • Ping Han
  • Qiang Wei
  • Hong Shen
Review Article

Abstract

This study aims to evaluate the efficacy and safety of solifenacin for treating overactive bladder. Randomized controlled trials (RCTs) were identified and extracted from MEDLINE, Embase, and CENTRAL. The quality of the included RCTs was assessed using the Jadad score, and heterogeneity was analyzed using the chi-squared test. The data of the included RCTs were collected, extracted, and assessed by our protocol. A total of nine RCTs were identified from the search strategy. Compared with the placebo and tolterodine treatments, both short-term (mostly 12-week) trials indicated that solifenacin significantly reduced urgency episodes, micturitions, and incontinence episodes per 24 h. Compared with the solifenacin (5 mg) group, the solifenacin (10 mg) group was significantly better in terms of the number of micturitions per 24 h. With regard to adverse effects, the patients treated with solifenacin had significantly higher rates of constipation and blurred vision than patients treated with tolterodine. The solifenacin therapy was not inferior to tolterodine in terms of efficacy profiles and had a similar incidence of overall adverse events compared with tolterodine treatment. Solifenacin (5 mg) is thus a recommended dose because of its reported balance between efficacy and acceptable tolerability.

Keywords

Solifenacin Overactive bladder Tolterodine 

References

  1. 1.
    Abrams P, Cardozo L, Fall M et al (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation subcommittee of the International Continence Society. Urology 61(1):37–49PubMedCrossRefGoogle Scholar
  2. 2.
    Milsom I, Abrams P, Cardozo L et al (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87(9):760–766PubMedCrossRefGoogle Scholar
  3. 3.
    Chapple CR (2007) Advancing the management of overactive bladder: new data, new directions. Eur Urol Suppl 6:1–3CrossRefGoogle Scholar
  4. 4.
    Reeves P, Irwin D, Kelleher C et al (2006) The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50:1050–1057PubMedCrossRefGoogle Scholar
  5. 5.
    Hampel C (2007) Long-term management of overactive bladder with antimuscarinic agents. Eur Urol Suppl 6:432–437CrossRefGoogle Scholar
  6. 6.
    Chapple CR, Martinez-Garcia R, Selvaggi L et al (2005) A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 48:464–470PubMedCrossRefGoogle Scholar
  7. 7.
    Choo MS, Lee JB, Kim YH et al (2008) Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomized, prospective, double-blind, multicentre study. Int J Clin Pract 62(11):1675–1683PubMedCrossRefGoogle Scholar
  8. 8.
    Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12PubMedCrossRefGoogle Scholar
  9. 9.
    Cardozo L, Hessdörfer E, Milani R, SUNRISE Study Group et al (2008) Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 102(9):1120–1127PubMedCrossRefGoogle Scholar
  10. 10.
    Karram MM, Toglia MR, Serels SR et al (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 73(1):14–18PubMedCrossRefGoogle Scholar
  11. 11.
    Toglia MR, Serels SR, Laramée C et al (2009) Solifenacin for overactive bladder: patient-reported outcomes from a large placebo-controlled trial. Postgrad Med 121(5):151–158PubMedCrossRefGoogle Scholar
  12. 12.
    Toglia MR, Ostergard DR, Appell RA et al (2010) Solifenacin for overactive bladder: secondary analysis of data from VENUS based on baseline continence status. Int Urogynecol J Pelvic Floor Dysfunct 21(7):847–854CrossRefGoogle Scholar
  13. 13.
    Serels SR, Toglia MR, Forero-Schwanhaeuser S et al (2010) Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms. Curr Med Res Opin 26(10):2277–2285PubMedCrossRefGoogle Scholar
  14. 14.
    Chapple CR, Fianu-Jonsson A, Indig M et al (2007) STAR study group. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg. Eur Urol 52(4):1195–1203PubMedCrossRefGoogle Scholar
  15. 15.
    Chapple CR, Rechberger T, Al-Shukri S et al (2004) YM-905 Study Group. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93(3):303–310PubMedCrossRefGoogle Scholar
  16. 16.
    Ho CH, Chang TC, Lin HH et al (2010) Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms. J Formos Med Assoc 109(10):702–708PubMedCrossRefGoogle Scholar
  17. 17.
    Chapple CR, Araño P, Bosch JL et al (2004) Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo- and tolterodine-controlled phase 2 dose-finding study. BJU Int 93(1):71–77PubMedCrossRefGoogle Scholar
  18. 18.
    Vardy MD, Mitcheson HD, Samuels TA et al (2009) Effects of solifenacin on overactive bladder symptoms, symptom bother and other patient-reported outcomes: results from VIBRANT—a double-blind, placebo-controlled trial. Int J Clin Pract 63(12):1702–1714PubMedCrossRefGoogle Scholar
  19. 19.
    Cardozo L, Lisec M, Millard R et al (2004) Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol 172(5 Pt 1):1919–1924PubMedCrossRefGoogle Scholar
  20. 20.
    Michel MC, de la Rosette JJ (2005) Role of muscarinic receptor antagonists in urgency and nocturia. BJU Int 96(suppl 1):37–42PubMedCrossRefGoogle Scholar
  21. 21.
    Landis RJ, Kaplan S, Swift S et al (2004) Efficacy of antimuscarinic therapy for overactive bladder with varying degree of incontinence severity. J Urol 171:752–756PubMedCrossRefGoogle Scholar
  22. 22.
    Staskin DR, MacDiarmid SA (2006) Pharmacologic management of overactive bladder: practical options for the primary care physician. Am J Med 119:24–28PubMedCrossRefGoogle Scholar
  23. 23.
    Alhasso AA, McKinlay J, Patrick K et al (2006) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 18(4):CD003193Google Scholar
  24. 24.
    Epstein BJ, Gums JG, Molina E (2006) Newer agents for the management of overactive bladder. Am Fam Physician 74:2061–2068PubMedGoogle Scholar
  25. 25.
    Chapple CR, Khullar V, Gabriel Z et al (2008) The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54:543–562PubMedCrossRefGoogle Scholar
  26. 26.
    Eglen RM, Hedge SS, Watson N (1996) Muscarinic receptor subtypes and smooth function. Pharmacol Rev 48:531–565PubMedGoogle Scholar
  27. 27.
    Haab F, Van Kerrebroeck P, Huang M, et al (2004) Solifenacin associated with high persistence on therapy in long-term overactive bladder extension study Third International consultation on Incontinence; June 26–28 (Monte Carlo): MonacoGoogle Scholar
  28. 28.
    Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55(Suppl 5A):33–46PubMedCrossRefGoogle Scholar
  29. 29.
    Ginsberg DA, Phillips SE, Wallace J et al (2007) Evaluating and managing constipation in the elderly. Urol Nurs 27:191–200PubMedGoogle Scholar
  30. 30.
    Rosenberg MT, Newman DK, Tallman CT et al (2007) Overactive bladder: recognition requires vigilance for symptoms. Cleve Clin J Med 74(Suppl 3):S21–S29PubMedCrossRefGoogle Scholar
  31. 31.
    Abrams P, Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100:987–1006PubMedCrossRefGoogle Scholar

Copyright information

© The International Urogynecological Association 2012

Authors and Affiliations

  • Deyi Luo
    • 1
  • Liangren Liu
    • 1
  • Ping Han
    • 1
  • Qiang Wei
    • 1
  • Hong Shen
    • 1
  1. 1.Department of Urology, West China HospitalSichuan UniversityChengduPeople’s Republic of China

Personalised recommendations